Conagra Brands launches Banquet MEGA Breakfast Bowls, a high-protein frozen line using a novel steaming method, signaling a strategic push into convenience-focused breakfast and testing investor appetite for its turnaround narrative.
A recent adjustment to Airgain's price target by analysts reflects a broader reassessment of the wireless connectivity specialist's prospects, underscoring how evolving narratives, rather than single events, are reshaping investor views on the stock.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
South Korean e-commerce giant Coupang is confronting a multi-front crisis, including class-action lawsuits and regulatory probes, following a data breach impacting millions. The fallout has led to the CEO's resignation and intensified scrutiny of corporate governance and cybersecurity protocols.
Starbucks announces a significant expansion of U.S. recycling access for its polypropylene cold cups, a move that intertwines environmental goals with investor considerations amid mixed financial performance.
Fresh financial data from QuidelOrtho reveals ongoing challenges, including constant currency revenue declines and pressured cash flow, forcing investors to weigh the stock's risk-reward profile as its momentum appears to fade.
Verizon Communications (VZ) surged nearly 12% after a robust Q4 2023 report, record postpaid growth, and a major share repurchase program. The telecom giant's confident 2026 outlook and strategic acquisition of Frontier assets signal a potential pivot, though questions about debt and valuation persist.
Vulcan Materials shares have more than doubled over five years, but new analysis suggests the construction aggregate giant's stock may now be trading at a premium to its intrinsic value, raising questions for potential investors.
Meta Platforms' stock has surged nearly 300% over three years, fueled by aggressive AI investments and cost discipline. As shares hover near record highs, investors are asking: does the current price still offer value, or has the rally priced in all future growth? A deep dive into valuation metrics suggests the story may be more nuanced than headlines imply.
Intel's bid to become a major contract chipmaker receives a significant boost as tech giants Apple and Nvidia engage in talks to shift portions of their advanced semiconductor manufacturing to Intel's U.S. facilities, challenging the long-standing dominance of TSMC and Samsung.
In a scathing letter, New York's Attorney General and top DAs accuse the federal GENIUS Act of enabling stablecoin giants to profit from illicit funds while denying restitution to victims, setting the stage for a legal and political clash.
While quantum computing startups capture headlines, IBM's decades-long investment and recent Nighthawk processor breakthrough are drawing serious capital from institutional investors, signaling enduring dominance in the enterprise quantum race.
French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.
Bitcoin plunged to levels not seen since before the 2024 U.S. election, caught in a broad sell-off of speculative assets. A sharp downturn in gold and silver prices triggered a massive $2.5 billion liquidation event, compounding existing pressures from fading regulatory optimism and a shifting Fed outlook.
Bitcoin clawed back some of its steep weekend losses in Monday trading, though the broader digital asset sector and related equities remained under significant selling pressure as investors digested a wave of forced liquidations and awaited key U.S. economic data.
While Medtronic's shares have trailed the S&P 500 over the past year, Wall Street maintains a cautiously optimistic stance, buoyed by strong recent earnings and raised guidance.
Novo Nordisk's experimental combination therapy CagriSema has demonstrated superior blood sugar control and weight loss compared to its own blockbuster Wegovy in a major Phase 3 trial. However, the emerging data suggests it may still trail behind Eli Lilly's rival drug Zepbound in key efficacy measures, setting the stage for a fierce market battle.
Once a rarity, multi-million-dollar home sales are now reshaping Thurston County's luxury real estate landscape, with a dozen properties crossing the $2 million threshold in 2025 alone—a sign of post-pandemic market transformation.
Columbia Financial (NASDAQ: CLBK) has announced a definitive agreement to merge with Northfield Bancorp in an all-stock transaction valued at approximately $597 million. The deal, slated to close in early Q3 2026, coincides with Columbia's planned "second-step" conversion to a fully public company, a move executives say will unlock value and create a leading regional bank in the New Jersey-New York metro area.
The Ermenegildo Zegna Group reported a resilient 2025, with full-year revenues reaching €1.92 billion. A strong fourth-quarter acceleration, driven by a 10% surge in direct-to-consumer sales, underscores the luxury group's strategic pivot away from wholesale. While the Americas and EMEA regions showed robust growth, Greater China remains a volatile market as the company navigates a planned leadership transition and industry headwinds.
